Überernährung an einer westlichen Diät ist häufig durch eine erhöhte Fettleibigkeit und eine neuronale Entzündungsreaktion im Hypothalamus gekennzeichnet. Der Hypothalamus ist für die Regulation der Energiehomöostase und der Nahrungsaufnahme von entscheidender Bedeutung. Klinische Daten belegen, dass die neuropathologische Inflammation auch nach einem Gewichtsverlust aufgrund einer Kalorienrestriktion bestehen bleibt. Die bariatrische Chirurgie wie der Roux-en-Y Magenbypass gehört in der Behandlung der Adipositas bisher zu den effektivsten Therapieansätzen, da sie im Vergleich zur Kalorienrestriktion zu einem deutlichen und langanhaltenden Gewichtsverlust führt. Bisher wurden die Auswirkungen des Roux-en-Y Magenbypass auf den Hypothalamus nicht erforscht. In der vorliegenden Arbeit wurde die Wirkung des Roux-en-Y Magenbypass auf die Entzündungsprozesse im Hypothalamus und die Auswirkung auf die Leptin-Sensitivität im Vergleich zur Kalorienrestriktion untersucht. Unter Verwendung der RT-qPCR- und der Western Blot-Methodik wurde die Expression spezifischer Marker im Hypothalamus untersucht, die an einem vermehrten Zellstress im ER und aktivierten Mikroglia im Gehirn der Ratten beteiligt sind. Postoperativ wurde die zirkulierende Leptinkonzentration im Blutplasma der Tiere gemessen und für die Testung der Leptin-Sensitivität nach exogener Leptinzufuhr das Essverhalten der Tiere beobachtet. Die Untersuchungen zeigten, dass der Roux-en-Y Magenbypass zu einer deutlichen Gewichtsreduktion und einem verminderten Konsum an hochkalorischer Nahrung führt. Im Hypothalamus zeigten sich im Vergleich zur diätetischen Kalorienrestriktion eine verminderte Aktivität der Mikroglia und eine reduzierte Inflammation. Außerdem zeigte sich eine deutlich erhöhte Leptinsensitivität mit reduzierter Nahrungsaufnahme nach exogener Leptin-Injektion. Der Roux-en-Y Magenbypass führt im Vergleich zur diätetischen Kalorienrestriktion zu einer Reduktion der Inflammation im Hypothalamus und zu einer verbesserten Leptinsensitivität. Dies könnte die unterschiedliche Effektivität in den Langzeitergebnissen des Roux-en-Y Magenbypass im Vergleich zur diätetischen Kalorienzufuhr begründen.

The purpose of this study was to determine if post-operative serum albumin and percentage of weight loss improved in patients who received formalized pre-operative nutrition counseling. Nutrition intervention was measured quantitatively. A retrospective review of records was conducted on 77 RYGB patients (68 female subjects and 9 male subjects), ages 21-64, during January 2001 through January 2006. The results indicated that patients who received pre-operative nutrition intervention had better clinical outcomes of serum albumin than those with no nutrition intervention from a registered dietitian. However, outcomes regarding percentage of weight loss varied. Both pre-operatively and at the 3 month post-operative visit the weight of subjects who received nutrition intervention seemed to be increasing by the 6 month post-operative visit the subjects with no nutrition intervention had lost more weight.

Background. Roux-en-Y gastric bypass (RYGB) is an effective treatment for obesity, where gut peptides such as ghrelin, glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) play an instrumental role in reduced appetite after RYGB. This systematic review and meta-analysis aimed to establish the magnitude of change of ghrelin, GLP-1, PYY and appetite sensation following RYGB. Methods. A systematic search was conducted in Medline Ovid, Embase, Scopus, and Cochrane Central Register of Controlled Trials up until March 2021. Two independent reviewers screened articles for studies that evaluated ghrelin, GLP-1, PYY or appetite sensation via visual analogue scales (VAS) before and after RYGB in adults. Risk of bias was assessed with the quality assessment tool for before-after studies with no control group from the National Heart, Lung and Blood Institute (NHLBI). A multilevel model with random effects for study and follow-up time points nested in study was fit to the data. The model included kilocalorie consumption as a covariate and time points as moderators. Results. Among the 2,559 articles identified, 47 met the inclusion criteria, among which k=19 evaluated ghrelin, k=40 GLP-1, k=22 PYY and k=8 appetite sensation via VAS. Our results indicate that fasting ghrelin levels are decreased 2 weeks post-RYGB (p = .005) but do not differ from baseline from 6 weeks to 1-year post-RYGB. Postprandial ghrelin levels at 6 months and 1-year post-RYGB were not different from pre-surgical values (p = .51). Fasting GLP-1 levels were not different from pre-surgical levels up to 2 years post-RYGB. Postprandial levels of GLP-1 increased significantly from 1 week (p < .001) to 2 years post-RYGB (p < .01) compared to before surgery. Compared to pre-RYGB levels, fasting PYY increased at 6 months (p = .034) and 1 year (p = .0299) post-surgery and postprandial levels were increased up to 1 year (p < .01). Heterogeneity was significant in most analyses. Insufficient data on appetite sensation was available to be meta-analyzed. Conclusion. Our analyses illustrate the magnitude of change of ghrelin, GLP-1 and PYY before and after RYGB surgery. Importantly, between study heterogeneity within the current literature warrants more standardized protocols and studies with longer follow-up periods for better comprehension of changes in gut peptides following RYGB surgery.

Le DT2 est caractérise par un défaut combiné de la sécrétion et de l’action de l’insuline. Depuis près d’un demi siècle la chirurgie bariatrique et notamment le Roux-en-Y Gastric Bypass (RYGB) ont montré des effets spectaculaires sur le contrôle glycémique remettant en question le paradigme de la prise en charge médicale du DT2. L’exclusion gastro duodénale induite par le RYGB améliore le métabolisme glucidique indépendemment de la perte de poids. Ainsi les modifications du flux biliaire semblent jouer un rôle, cependant les mécanismes sous-jacents ne sont pas clairs. Nous avons réalisés des RYGB chez le miniporc et nous avons montré que l'absorption intestinale du glucose est diminuée dans l’anse alimentaire (AL) dépourvue de bile. L'absorption du glucose dans l’AL était restaurée par l'ajout de la bile, et cet effet était inhibé lorsque le co transport actif sodium glucose 1 (SGLT1) était bloquée par la phlorizine. SGLT1 restait exprimée dans la AL, cependant la teneur dans la lumière de l’intestin en sodium était nettement diminuée. L’ajout de sodium dans l'AL provoquait le même effet que la bile sur l'absorption du glucose et augmentait également l’excursion glycémique post prandiale chez le miniporc au cours d’un repas test vigil. La diminution de l'absorption intestinale du glucose après RYGB a ensuite été confirmée chez l'homme. Nos résultats démontrent que la l’exclusion biliaire affecte le métabolisme post prandiale du glucose par modulation des co transporteurs intestinaux sodium-glucose. / Type 2 diabetes (T2D) is characterized primarily as a combined defect of insulin secretion and insulin action. For nearly a decade, the somewhat mysterious but spectacular benefit of metabolic surgery, and more specifically of Roux-en-Y gastric bypass (RYGB), on glucose control has been caused a questioning the current paradigm of T2D management. Gastro-intestinal exclusion by RYGB improves glucose metabolism, independent of weight loss. Although changes in intestinal bile trafficking have been shown to play a role, the underlying mechanisms are unclear. We performed RYGB in minipigs and showed that the intestinal uptake of ingested glucose is blunted in the bile deprived alimentary limb (AL). Glucose uptake in the AL was restored by the addition of bile, and this effect was abolished when active glucose intestinal transport was blocked with phlorizin. Sodium-glucose cotransporter 1 remained expressed in the AL, while intraluminal sodium content was markedly decreased. Adding sodium to the AL had the same effect as bile on glucose uptake. It also increased postprandial blood glucose response in conscious minipigs following RYGB. The decrease in intestinal uptake of glucose after RYGB was confirmed in humans. Our results demonstrate that bile diversion affects postprandial glucose metabolism by modulating sodium-glucose intestinal cotransport.

Einleitung Angesichts des besorgniserregenden Anstiegs der weltweiten Inzidenz von Übergewicht und Adipositas sowie der damit assoziierten Komorbiditäten, bedarf es neben weitreichenden präventiven Maßnahmen vor allem der Entwicklung neuer, nachhaltig effizienter Strategien zum langfristigen Gewichts- und Stoffwechselmanagement. Als wichtiger Ausgangspunkt für solch non-invasive Behandlungsalternativen, könnte das Verständnis der zugrundeliegenden Wirkmechanismen der „bariatrisch-metabolischen Chirurgie“, mit dem Roux-en-Y Magenbypass (Roux-en-Y gastric bypass, RYGB) als eines der am häufigsten angewandten Verfahren, genutzt werden. Zumal der langfristige Erfolg der RYGB-Operation nicht nur auf die restriktiv-malabsorptiven Modifikationen zurückzuführen ist, sondern auch mit zahlreichen vom Gewichtsverlust unabhängigen Faktoren, wie einer erheblichen Umgestaltung der mikrobiellen Darmbesiedlung, in Verbindung gebracht wird. Inwieweit es sich hierbei um eine kausale Verbindung zwischen der RYGB-modulierten intestinalen Mikrobiota und den durch den chirurgischen Eingriff induzierten Gesundheitsvorteilen handelt, blieb bislang jedoch ungeklärt. Ziel der Untersuchung Die vorliegende Arbeit dient der Darstellung der funktionellen Beziehung zwischen der RYGB-spezifischen Darm-Mikrobiota und den positiven therapeutischen Effekten der Roux-en-Y Magenbypass-Operation bei diätetisch-induzierter Adipositas. Hierbei ist vor allem die Rolle der postoperativen „RYGB-Mikrobiota“ beim Erreichen der nachhaltigen Gewichtsreduktion und verbesserten Stoffwechselfunktion von besonderem Interesse. Im Weiteren wird die Mikrobiota-basierte Übertragbarkeit jener vorteilhaften Auswirkungen des bariatrischen Eingriffs auf ein konventionelles Adipositasmodell untersucht. Ergebnisse Mithilfe der gezielten Dezimierung der mikrobiellen Darmflora von RYGB-operierten Tieren, ließ sich die grundlegende Bedeutung derselben für die postoperativen Verbesserungen der Gewichts-, Stoffwechsel- und Energiekontrolle des Wirtes verdeutlichen. So führte die kontinuierliche Antibiotikagabe zu einer signifikanten Minderung der positiven klinischen Effekte des Eingriffes, was als Beweis für die essenzielle Bedeutung der intestinalen „RYGB-Mikrobiota“ zum Erreichen des vollen Ausmaßes der therapeutischen Wirksamkeit der Operation bewertet werden kann. Basierend auf Versuchen, die die Übertragbarkeit bariatrischer Therapieeffekte auf keimfreie, metabolisch unbelastete Versuchstiere belegen, gelang es uns zudem nachzuweisen, dass der fäkale Mikrobiota-Transfer der post-RYGB veränderten mikrobiellen Darmbesiedlung auch bei konventionell aufgezogenen, nicht-operierten Kleinnagern mit diätetisch-induzierter Adipositas ausreicht, um die positiven Auswirkungen der Operation auf die Stoffwechselgesundheit des Empfängers nachzuahmen. Schlussfolgerungen So unterstreichen die Ergebnisse unseres konventionellen Adipositas-Krankheitsmodells zum einen die entscheidende Rolle der intestinalen Mikrobiota als Schlüsselfaktor für den Operationserfolg des Roux-en-Y Magenbypasses und veranschaulichen zum anderen eine innovative Möglichkeit zur Behandlung von Adipositas und den damit verbundenen Stoffwechselerkrankungen auf der Grundlage von Mikrobiota-Modulation.:INHALTSVERZEICHNIS 1 EINLEITUNG 2 LITERATURÜBERSICHT 2.1 Adipositas in unserer Gesellschaft 2.2 Therapiemöglichkeiten von Adipositas 2.2.1 konservative Behandlungsansätze 2.2.2 bariatrische Chirurgie 2.3 Auswirkungen der Roux-en-Y Magenbypass-Operation auf das Körpergewicht, den Stoffwechsel und die intestinale Mikrobiota bei Adipositas 2.4 Rolle der intestinalen Mikrobiota bei physiologischen und pathologischen Stoffwechselprozessen im Wirtsorganismus 2.5 Behandlung von Darmerkrankungen und extraintestinalen Krankheiten durch fäkalen Mikrobiota-Transfer 2.6 Evidenz für die Übertragung des metabolischen Phänotyps durch fäkalen Mikrobiota-Transfer 2.7 Bisherige Evidenz zur Wirkung der nach RYGB-Operation modulierten intestinalen Mikrobiota auf den Wirtsstoffwechsel 2.8 Fragestellungen und Hypothesen 3 TIERE, MATERIALIEN UND METHODEN 3.1 Versuchstiere 3.2 Materialien 3.2.1 Materialien des allgemeinen Versuchsablaufs und der In-vivo-Tests 3.2.2 Materialien der Roux-en-Y Magenbypass-Operation 3.2.3 Materialien der Ex-vivo-Analysen 3.3 Methoden 3.3.1 Allgemeiner Versuchsablauf 3.3.2 Roux-en-Y Magenbypass-Operation in der Ratte 3.3.2.1 Präoperative Versorgung 3.3.2.2 OP-Ablauf 3.3.2.3 Postoperative Versorgung 3.3.3 In-vivo-Tests 3.3.3.1 Glukosetoleranztest 3.3.3.2 Insulintoleranztest 3.3.3.3 Kälteexposition und Wärmebildaufnahme 3.3.3.4 Echo MRI 3.3.4 Ex-vivo-Analysen 3.3.4.1 Gewebeentnahme und -konservierung 3.3.4.2 Histologische Gewebeaufarbeitung 3.3.4.2.1 Generierung histologischer Gewebeschnitte 3.3.4.2.2 Immunhistochemische/Histologische Färbeverfahren 3.3.4.2.3 Mikroskopische Gewebsanalyse 3.3.4.3 Absorptionsphotometrie 3.3.4.4 Statistische Auswertung 4 ERGEBNISSE 4.1 Dezimierung der intestinalen Mikrobiota post-RYGB beeinflusst die therapeutischen Effekte der operativen Intervention auf den Wirtsorganismus 4.1.1 Dezimierung der „RYGB-Mikrobiota“ verändert den Einfluss der Operation auf die Futterpräferenz, Energiezufuhr und das Körpergewicht 4.1.2 Dezimierung der „RYGB-Mikrobiota“ modifiziert die Auswirkungen der chirurgischen Intervention auf die Glukose-Homöostase 4.1.3 Dezimierung der „RYGB-Mikrobiota“ beeinflusst die Folgen des bariatrischen Eingriffs auf den Lipidmetabolismus 4.1.4 Auswirkung der Dezimierung der „RYGB-Mikrobiota“ auf die postoperativ auftretenden Veränderungen des Energiehaushaltes (Thermogenese) 4.1.5 Dezimierung der „RYGB-Mikrobiota“ verändert die Effekte der Operation auf die Morphologie des Darms 4.2 Übertragung der post-RYGB veränderten intestinalen Mikrobiota auf ein konventionelles Adipositasmodell imitiert die therapeutischen Effekte der operativen Intervention 4.2.1 Einfluss des Transfers der fäkalen „RYGB-Mikrobiota“ auf die Futterpräferenz, Energiezufuhr und das Körpergewicht im konventionellen Adipositasmodell 4.2.2 Auswirkung des Transfers der fäkalen „RYGB-Mikrobiota“ auf die Glukose- Homöostase im konventionellen Adipositasmodell 4.2.3 Beeinflussung des Lipidmetabolismus durch den Transfer der fäkalen „RYGB-Mikrobiota“ im konventionellen Adipositasmodell 4.2.4 Veränderung des Energiehaushaltes (Thermogenese) durch den Transfer der fäkalen „RYGB-Mikrobiota“ im konventionellen Adipositasmodell 4.2.5 Transfer der fäkalen „RYGB-Mikrobiota“ modifiziert die Morphologie des Darms im konventionellen Adipositasmodell 5 DISKUSSION 5.1 Kausale Rolle der postoperativ veränderten intestinalen „RYGB-Mikrobiota“ für den Therapieerfolg der Operation 5.2 Therapeutische Bedeutung der RYGB-spezifischen intestinalen Mikrobiota auf Gewicht und Stoffwechsel bei konventioneller Adipositas 5.3 Fazit und Ausblick 6 ZUSAMMENFASSUNG 7 SUMMARY 8 LITERATURVERZEICHNIS / Introduction In view of the alarming increase in the global incidence of overweight and obesity and the associated comorbidities, there is a particular need for the development of new, sustainably efficient strategies for long-term weight and metabolic management, in addition to far-reaching preventive measures. As an important starting point for such noninvasive treatment alternatives, the understanding of the underlying mechanisms of action of 'bariatric metabolic surgery', with Roux-en-Y gastric bypass (RYGB) as one of the most commonly used procedures, could be used. Especially since the long-term success of RYGB surgery is not only due to the restrictive malabsorptive modifications, but also associated with numerous factors independent of weight loss, such as significant transformation of the intestinal microbial colonization. However, the extent to which this constitutes a causal link between the RYGB-modulated intestinal microbiota and the health benefits induced by the surgical intervention has so far remained unclear. Aims of the Study The aim of this investigation is to present the functional relationship between the RYGB-specific gut microbiota and the beneficial therapeutic effects of Roux-en-Y gastric bypass surgery for diet-induced obesity. Here, the role of the postoperative 'RYGB-microbiota' in achieving sustained weight loss and improved metabolic function is of particular interest. Furthermore, the microbiota-based transferability of those beneficial effects of bariatric surgery to a conventional obesity model is investigated. Results Using deliberate depletion of the intestinal microbial flora of RYGB-operated animals, our experiments in the RYGB small animal model allowed us to elucidate the fundamental importance of surgery-induced modulation of the intestinal microbiota for the postoperative improvements in the host's weight as well as metabolic, and energy control. In fact, continuous administration of antibiotics significantly attenuated the beneficial clinical effects of the Roux-en-Y gastric bypass, which can be interpreted as evidence of the essential importance of the intestinal 'RYGB-microbiota' for the full extent of the therapeutic efficacy of surgery. Based on experiments demonstrating the transferability of the effects of bariatric therapy to germ-free, metabolically unaffected experimental animals, we were also able to demonstrate that fecal microbiota transfer of the altered post-RYGB intestinal microbial colonization was sufficient to mimic the beneficial effects of surgery on the metabolic health of the recipient, even in non-operated, conventionally reared small rodents with diet-induced obesity. Conclusions Thus, the results of our conventional obesity disease model both highlight the critical role of intestinal microbiota as a key factor in the surgical success of Roux-en-Y gastric bypass and illustrate an innovative way to treat obesity and associated metabolic diseases through microbiota modulation.:INHALTSVERZEICHNIS 1 EINLEITUNG 2 LITERATURÜBERSICHT 2.1 Adipositas in unserer Gesellschaft 2.2 Therapiemöglichkeiten von Adipositas 2.2.1 konservative Behandlungsansätze 2.2.2 bariatrische Chirurgie 2.3 Auswirkungen der Roux-en-Y Magenbypass-Operation auf das Körpergewicht, den Stoffwechsel und die intestinale Mikrobiota bei Adipositas 2.4 Rolle der intestinalen Mikrobiota bei physiologischen und pathologischen Stoffwechselprozessen im Wirtsorganismus 2.5 Behandlung von Darmerkrankungen und extraintestinalen Krankheiten durch fäkalen Mikrobiota-Transfer 2.6 Evidenz für die Übertragung des metabolischen Phänotyps durch fäkalen Mikrobiota-Transfer 2.7 Bisherige Evidenz zur Wirkung der nach RYGB-Operation modulierten intestinalen Mikrobiota auf den Wirtsstoffwechsel 2.8 Fragestellungen und Hypothesen 3 TIERE, MATERIALIEN UND METHODEN 3.1 Versuchstiere 3.2 Materialien 3.2.1 Materialien des allgemeinen Versuchsablaufs und der In-vivo-Tests 3.2.2 Materialien der Roux-en-Y Magenbypass-Operation 3.2.3 Materialien der Ex-vivo-Analysen 3.3 Methoden 3.3.1 Allgemeiner Versuchsablauf 3.3.2 Roux-en-Y Magenbypass-Operation in der Ratte 3.3.2.1 Präoperative Versorgung 3.3.2.2 OP-Ablauf 3.3.2.3 Postoperative Versorgung 3.3.3 In-vivo-Tests 3.3.3.1 Glukosetoleranztest 3.3.3.2 Insulintoleranztest 3.3.3.3 Kälteexposition und Wärmebildaufnahme 3.3.3.4 Echo MRI 3.3.4 Ex-vivo-Analysen 3.3.4.1 Gewebeentnahme und -konservierung 3.3.4.2 Histologische Gewebeaufarbeitung 3.3.4.2.1 Generierung histologischer Gewebeschnitte 3.3.4.2.2 Immunhistochemische/Histologische Färbeverfahren 3.3.4.2.3 Mikroskopische Gewebsanalyse 3.3.4.3 Absorptionsphotometrie 3.3.4.4 Statistische Auswertung 4 ERGEBNISSE 4.1 Dezimierung der intestinalen Mikrobiota post-RYGB beeinflusst die therapeutischen Effekte der operativen Intervention auf den Wirtsorganismus 4.1.1 Dezimierung der „RYGB-Mikrobiota“ verändert den Einfluss der Operation auf die Futterpräferenz, Energiezufuhr und das Körpergewicht 4.1.2 Dezimierung der „RYGB-Mikrobiota“ modifiziert die Auswirkungen der chirurgischen Intervention auf die Glukose-Homöostase 4.1.3 Dezimierung der „RYGB-Mikrobiota“ beeinflusst die Folgen des bariatrischen Eingriffs auf den Lipidmetabolismus 4.1.4 Auswirkung der Dezimierung der „RYGB-Mikrobiota“ auf die postoperativ auftretenden Veränderungen des Energiehaushaltes (Thermogenese) 4.1.5 Dezimierung der „RYGB-Mikrobiota“ verändert die Effekte der Operation auf die Morphologie des Darms 4.2 Übertragung der post-RYGB veränderten intestinalen Mikrobiota auf ein konventionelles Adipositasmodell imitiert die therapeutischen Effekte der operativen Intervention 4.2.1 Einfluss des Transfers der fäkalen „RYGB-Mikrobiota“ auf die Futterpräferenz, Energiezufuhr und das Körpergewicht im konventionellen Adipositasmodell 4.2.2 Auswirkung des Transfers der fäkalen „RYGB-Mikrobiota“ auf die Glukose- Homöostase im konventionellen Adipositasmodell 4.2.3 Beeinflussung des Lipidmetabolismus durch den Transfer der fäkalen „RYGB-Mikrobiota“ im konventionellen Adipositasmodell 4.2.4 Veränderung des Energiehaushaltes (Thermogenese) durch den Transfer der fäkalen „RYGB-Mikrobiota“ im konventionellen Adipositasmodell 4.2.5 Transfer der fäkalen „RYGB-Mikrobiota“ modifiziert die Morphologie des Darms im konventionellen Adipositasmodell 5 DISKUSSION 5.1 Kausale Rolle der postoperativ veränderten intestinalen „RYGB-Mikrobiota“ für den Therapieerfolg der Operation 5.2 Therapeutische Bedeutung der RYGB-spezifischen intestinalen Mikrobiota auf Gewicht und Stoffwechsel bei konventioneller Adipositas 5.3 Fazit und Ausblick 6 ZUSAMMENFASSUNG 7 SUMMARY 8 LITERATURVERZEICHNIS

Η παχυσαρκία και οι σχετιζόμενες με αυτήν παθολογικές καταστάσεις συνιστούν μία από τις κυριότερες αιτίες θανάτου παγκοσμίως, με τα επίπεδά της να αυξάνονται σε ανησυχητικό βαθμό. Επιδημιολογικές έρευνες σε ασθενείς με μεταβολικό σύνδρομο έδειξαν ευθεία συσχέτιση μεταξύ παχυσαρκίας και χαμηλών επιπέδων HDL χοληστερόλης πλάσματος, ενώ μελέτες σε πειραματικά μοντέλα ποντικών αποδεικνύουν πως η συσχέτιση αυτή είναι αιτιολογική. Η HDL είναι ένα μίγμα λιποπρωτεϊνικών σωματιδίων που, ανάλογα με τη σύστασή τους σε λιπίδια, μπορούν να είναι δισκοειδή ή σφαιρικά. Η σημαντικότερη αθηροπροστατευτική δράση της HDL οφείλεται στο γεγονός ότι η συγκεκριμένη λιποπρωτεΐνη συλλέγει την περίσσεια χοληστερόλης από τους περιφερικούς ιστούς και τη μεταφέρει στο ήπαρ, όπου καταβολίζεται, μια διαδικασία γνωστή και ως ανάστροφη μεταφορά χοληστερόλης. Κύρια πρωτεΐνη της HDL είναι η απολιποπρωτεΐνη Α-Ι (apoA-I), η οποία αλληλεπιδρώντας με τον μεταφορέα λιπιδίων ABCA1 προάγει την de novo σύνθεση δισκοειδών HDL σωματιδίων, τα οποία μετατρέπονται σε σφαιρικά με τη δράση του ενζύμου LCAT. Μία πρόσφατη μελέτη έδειξε ότι οι απολιποπρωτεΐνες E (apoE) και CIII (apoCIII) είναι ικανές να προάγουν την de novo βιογένεση HDL σωματιδίων ανεξάρτητα από την apoA-I. Η παρατήρηση αυτή ενίσχυσε την ιδέα ότι ο πληθυσμός της HDL είναι ένας συνδυασμός διαφορετικών σωματιδίων που έχουν διακριτή απολιποπρωτεϊνική σύνθεση. Επιπλέον, μεταβολές στις αναλογίες των απολιποπρωτεϊνών της HDL φαίνεται να καθορίζουν την κατανομή και τη λειτουργικότητα των υποπληθυσμών της. Στην παρούσα μελέτη στόχος ήταν ο δομικός και λειτουργικός χαρακτηρισμός της HDL σε ασθενείς με υπερνοσογόνο παχυσαρκία που υποβλήθηκαν σε χολοπαγκρεατική εκτροπή με γαστρική παράκαμψη κατά Roux en Y. Μελετήθηκαν 20 ασθενείς με υπερνοσογόνο παχυσαρκία, πριν και μετά την χειρουργική επέμβαση, και 7 υγιή άτομα ελέγχου. Απομονώθηκε πλάσμα από την ομάδα ελέγχου και από τους 20 ασθενείς πριν την επέμβαση καθώς και έξι μήνες μετά. Ακολούθησε κλασματοποίηση λιποπρωτεινών του πλάσματος με υπερφυγοκέντρηση σε βαθμίδωση πυκνότητας KBr και ανάλυση των κλασμάτων με Western Blot για ανίχνευση και ποσοτικοποίηση των επιπέδων των απολιποπρωτεινών apoA-I, apoE και apoCIII. Ακολούθησαν περαιτέρω βιοχημικές αναλύσεις των κλασμάτων, δομικές αναλύσεις με μη αποδιατακτική ηλεκτροφόρηση δύο διαστάσεων (2D-PAGE) και ηλεκτρονική μικροσκοπία, προκειμένου να υπάρξει μία πιο ξεκάθαρη εικόνα για τα σωματίδια που απαρτίζουν την HDL ενώ μετρήθηκε και η αντιοξειδωτική ικανότητα της HDL και στις τρεις ομάδες. Τέλος, μετρήθηκε η δραστικότητα του ενζύμου LCAT και συσχετίστηκε με την ηπατική εναπόθεση τριγλυκεριδίων των ασθενών. Η σειρά αναλύσεων των λιποπρωτεϊνικών κλασμάτων με Western Blot έδειξε ότι, έξι μήνες μετά την επέμβαση, υπάρχει μείωση των απολιποπρωτεϊνών A-I, E και CIII των ασθενών. Τα αποτελέσματα από την δισδιάστατη ηλεκτροφόρηση και την ηλεκτρονική μικροσκοπία αποδεικνύουν την ύπαρξη διαφορετικών σωματιδίων της HDL με διακριτή απολιποπρωτεϊνική σύνθεση, ενώ η μέτρηση του αντιοξειδωτικού δυναμικού της HDL φανερώνει τη ύπαρξη πιο λειτουργικής HDL μετά την επέμβαση. Η αυξημένη δραστικότητα της LCAT στους ασθενείς σε σχέση με την ομάδα ελέγχου και η μείωσή της μετά την επέμβαση υποδηλώνει ένα πιθανό αντιρροπιστικό μηχανισμό για την αναστολη της συσσώρευσης δισκοειδούς HDL. Έτσι προάγεται ο σχηματισμός περισσότερης ώριμης σφαιρικής HDL, ενώ αποτρέπεται και η εναπόθεση ηπατικών τριγλυκεριδίων που παρατηρείται στο ήπαρ των ασθενών αυτών. Η παρατήρηση ότι η δομή και η λειτουργικότητα της HDL βελτιώνονται στους ασθενείς έξι μήνες μετά την επέμβαση, οδηγεί στο συμπέρασμα ότι η χειρουργική επέμβαση στην οποία υποβάλλονται οι ασθενείς επιδρά θετικά στην ποιότητα της HDL. / Obesity and its related pathologies are one of the leading causes of death worldwide, with levels increasing to an alarming extent. Epidemiological studies in patients with metabolic syndrome showed a direct correlation between obesity and low levels plasma of HDL cholesterol and experimental studies in mice show that this correlation is causative. HDL is a mixture of lipoprotein particles, which, depending on their composition in lipids, may be discoidal or spherical. The most important atheroprotective action of HDL is due to the fact that this lipoprotein collects excess cholesterol from peripheral tissues and transports it to the liver where it is catabolized. The main protein of the HDL is apolipoprotein A-I (apoA-I), which interacts with the lipid carrier ABCA1 and promotes de novo synthesis of discoidal HDL particles, which are converted to spherical with the LCAT enzyme. A recent study showed that apolipoprotein E (apoE) and CIII (apoCIII) areable to promote de novo biogenesis of HDL particles regardless of apoA-I. This observation supported the idea that the population of HDL is a combination of different particles with distinct apolipoprotein composition. Moreover, changes in the apolipoprotein ratiosof HDL appear to determine the distribution and function of its subpopulations. Although HDL cholesterol (HDL-C) has been traditionally associated to atheroprotection, recently it became clear that HDL particle functionality is also a key in reducing cardiovascular mortality. To this date the effects of obesity on HDL structure and functionality remain unclear. In this study, the objective was the structural and functional characterization of HDL frommorbidly obese patients undergoing biliopancreatic diversion by Roux en Y before and six months after the operation, and in lean control subjects. We studied 20 morbidly obese patients before and after surgery, and 7 control healthy individuals. Plasma was isolated from the control group and 20 patients before surgery and six months. Plasma was fractionated by KBr density gradient ultracentrifugation and lipoprotein fractions were isolated and analyzed, by Western Blot, for detection and quantification of the levels of apolipoproteins apoA-I, apoE and apoCIII. Further biochemical analysis of fractions, structural analysis with non denaturing two-dimensional electrophoresis (2D-PAGE) and electron microscopy, in order to have a more clear picture of the particles that compose HDL. In order to determine whether or how the efficiency of HDL is affected by the operation, we performed an assay measuring the antioxidant capacity of HDL in all three groups. Finally, the activity of the LCAT enzyme was measured and was correlated with the triglyceride deposition observed in the liver of these patients. The sequence analyzes of lipoprotein fractions by Western Blot showed that six months after surgery, there was a decrease in the levels of apolipoproteins AI, E and CIII. The results from the two-dimensional electrophoresis and electron microscopy showed the existence of different particles with distinct HDL apolipoprotein composition while the increased antioxidant potential of HDL indicates the existence of a more functional HDL after surgery. The increased activity of LCAT in patients plasma compared with the control group and its reduction after surgery, suggests that perhaps there may be a saving grace that tries to overcome the accumulation of discoidal HDL and promotes the formation of more mature, spherical HDL, so as to prevent the triglyceride deposition observed in the liver of these patients. The observation that the structure and function of HDL improved six months after surgery, leads to the conclusion that the surgery undergone by patients has a positive effect on the quality of HDL.

No description available.

INTRODUÇÃO: a cirurgia bariátrica tem se mostrado efetiva no tratamento de comorbidades relacionadas à obesidade como o Diabetes Mellitus tipo 2 (DM2), sugerindo que mecanismos além da perda de peso estão envolvidos. Diversos estudos têm atribuído a melhora da regulação glicêmica à secreção de incretinas pelo intestino distal, devido ao estímulo da rápida passagem de alimento por esta região; outra hipótese confere o resultado à exclusão do intestino proximal, porém detalhes dos mecanismos de ação e do seu papel em indivíduos não obesos ainda precisam ser esclarecidos. Indivíduos com DM2 operados por motivos diferentes da obesidade representam adequado modelo para analisar resultados clínicos da exclusão duodenal. OBJETIVO: analisar a mudança da glicemia em pacientes diabéticos submetidos a gastrectomia total ou subtotal com derivação em Y de Roux por câncer gástrico. PACIENTES E MÉTODOS: estudo observacional, analítico, tipo coorte com abordagem retrospectiva, desenvolvido em duas instituições públicas de saúde no município de São Paulo, aprovado por comitê de ética em pesquisa. Foram verificados os prontuários físicos e eletrônicos, com respeito às variáveis demográficas (sexo, idade) e clínicas (comorbidades, Índice de Massa Corpórea-IMC, glicemia de jejum, hemoglobina glicada e uso de medicamentos) antes da operação (T0) e um ano após (T1). A amostra foi composta por 129 pacientes acima de 18 anos, com diagnóstico de DM2 e Adenocarcinoma gástrico, submetidos a gastrectomia com reconstrução em Y de Roux. Foram excluídos 26 pacientes por falta de acompanhamento ou óbito antes de um ano de pós-operatório; a amostra de análise (n=103) foi representada por 50,5% (n=52) de mulheres e 49,5% homens (n=51), com idade média de 65,5 ± 9,57 anos (41-89 anos). A distribuição do IMC foi de 25 a 30 kg/m2 em 44,7% (n=46), abaixo de 25 kg/m2 em 38,8% (n=40) e maior que 30 kg/m2 em 16,5% (n=17). A gastrectomia subtotal foi realizada em 79,6% (n=82) dos pacientes. Para a análise estatística, usaram-se medidas de tendência central, teste t de Student e regressão logística com o modelo CART. RESULTADOS: após um ano de pós-operatório, a média de glicemia diminuiu de 147,6 mg/dL (T0) para 134 mg/dL (T1) (p=0,046), porém 70% dos pacientes com glicemia > 100 no T0 permaneceram com o mesmo valor no T1. A hemoglobina glicada não teve mudança significativa (7,5% no T0 vs 7,0% no T1, p=0,988). A média do IMC diminuiu de 26,5 kg/m2 (T0) para 24,3 kg/m2 (T1) (p < 0,001). Após um ano, 6,7% (n=6) tiveram suspensão da medicação com resolução do DM2 e 11,2% (n=10) diminuíram a medicação hipoglicemiante, enquanto que, em 60,7% (n=54), permaneceu inalterada e, em 21,4% (n=19), piorou. Os pacientes com IMC entre 30-35 kg/m2 foram os que tiveram melhor resposta em relação à normalização dos níveis glicêmicos. O modelo de regressão logística mostrou como preditores da mudança na medicação a idade ( < 62,5 anos) e o IMC ( > 30,2 kg/m2) com valor preditivo 71,4%. CONCLUSÕES: o estudo demonstrou que não houve melhora da glicemia nos pacientes com DM2 submetidos a gastrectomia total ou subtotal com reconstrução em Y Roux, com IMC abaixo de 30 kg/m2, nem foram observadas evidências que corroborem a Teoria do Intestino Proximal. Há indícios de que a cirurgia possa influenciar o controle glicêmico quando o IMC é > 30 kg/m2 e a idade, inferior a 62,5 anos / INTRODUCTION: Bariatric surgery has been shown to be effective in the treatment of obesity-related comorbidities such as Type 2 Diabetes Mellitus (DM2), suggesting that mechanisms in addition to weight loss are involved. Several studies have attributed the improvement of glycemic regulation to the secretion of incretins in the distal intestine, due to the stimulation of the fast passage of food by this region. Another hypothesis confers the result to the exclusion of the proximal intestine; however, details of the mechanisms of action and their role in non-obese individuals have yet to be clarified. Individuals with DM2 operated for other reasons than obesity, represent an adequate model to analyze clinical outcomes of duodenal exclusion. AIM: to analyze the glycemia changes in diabetic patients submitted to total or subtotal gastrectomy with Roux-en-Y derivation for gastric cancer. PATIENTS AND METHODS: An observational, analytical, cohort study with a retrospective approach, developed in two public health institutions in the city of São Paulo, approved by a research ethics committee. The physical and electronic charts concerning to demographics (sex, age) and clinical variables (comorbidities, Body Mass Index (BMI), fasting glycemia, glycated hemoglobin and medication use) were checked before surgery (T0) and one year after (T1). The sample consisted of 129 patients over 18 years of age, diagnosed with DM2 and Gastric Adenocarcinoma, who underwent gastrectomy with Roux-en-Y reconstruction. Twenty-six patients were excluded due to lack of follow-up or death before one year of postoperative; the analysis sample (n=103) was represented by women 50.5% (n=52) and 49.5% men (n=51), with a mean age of 65.5 years (SD=9.57; 41-89 years). The distribution of BMI was 25 to 30 kg/m2 in 44.7% (n=46), below 25 kg/m2 in 38.8% (n=40) and greater than 30 kg/m2 in 16.5 % (n=17). Subtotal gastrectomy was performed in 79.6% (n=82) of the patients. Statistical analysis used central tendency measures, Student\'s t-test and logistic regression with the CART model. RESULTS: After one year of postoperative, mean glucose levels decreased from 147.6 mg/dL (T0) to 134 mg/dL (T1) (p=0.046), but 70% of patients with glycemia > 100 at T0, remained with the same value in T1. Glycated hemoglobin had no significant change (7.5% in T0 vs. 7.0% in T1, p=0.988). The mean BMI decreased from 26.5 kg/m2 (T0) to 24.3 kg/m2 (T1) (p < 0.001). After one year, 6.7% (n=6) had discontinuation of the medication with the resolution of DM2, and 11.2% (n=10) decreased the hypoglycemic medication, while in 60.7% (n=54) there no was change, and in 21.4% (n=19) it worsened. Patients with BMI between 30-35 kg/m2 were the ones that had the best response regarding the normalization of glycemic levels. The logistic regression model showed predictors of change in medication, age ( < 62.5 years) and BMI ( > 30.2 kg/m2) with a predictive value of 71.4%. CONCLUSIONS: The study demonstrated that there was no improvement of glycemia in patients with DM2 who underwent total or subtotal gastrectomy with Roux-in-Y reconstruction, with a BMI below 30 kg/m2. No evidence was found corroborating the theory of the proximal intestine. There are indications that surgery may influence glycemic control when BMI > 30 kg/m2 and age less than 62.5 years

O tratamento cirúrgico para a obesidade mórbida é a única modalidade que consegue a perda de peso sustentada e manutenção a longo prazo. Dentre as técnicas cirúrgicas empregadas, a gastroplastia vertical com derivação gastrojejunal em Y de Roux é uma das mais empregadas mundialmente e em nosso meio. Através desta técnica, o estômago é dividido em duas partes assimétricas, uma vertical e tubular com cerca de 5 cm de extensão que faz parte do trânsito alimentar e outra denominada exclusa. O seguimento endoscópico pós-operatório de rotina, com o uso do endoscópio convencional, avalia o coto gástrico proximal, mas não alcança o estômago excluso. Com o advento do enteroscópio de duplo balão, tornou-se possível o acesso e avaliação endoscópica, permitindo a realização de biópsias da mucosa do estômago excluso para estudo histológico. Quarenta pacientes submetidos à gastroplastia vertical com derivação gastrojejunal em Y de Roux foram incluídos no estudo de maneira prospectiva, com período pós-operatório médio de 77,3 meses (36 - 133), idade média de 44,6 anos (22 - 61), sendo 85% do sexo feminino. O sucesso de acesso ao estômago excluso com a utilização do enteroscópio de duplo balão foi de 87,5% (35 pacientes), com tempo médio decorrido até o estômago excluso de 24,9 minutos (5 - 75). O controle radioscópico concomitante ao exame endoscópico para auxílio direcional foi utilizado em 11 pacientes (27,5 %). Os achados endoscópicos do estômago excluso nos 35 pacientes foram: normal em 9 pacientes(25,7 %); gastrite enantemática em 10 (28,6 %); gastrite erosiva plana ou elevada em 5 (14,3%); gastrite erosiva com sinais de hemorragia em 5 (14,3%) e gastrite atrófica em 6 (17,1 %), sendo que dois destes apresentavam concomitantemente áreas sugestivas de metaplasia intestinal no antro que foram confirmadas pelo estudo histológico. Quanto aos achados histológicos, observou-se 100% de gastrite no estômago excluso, sendo 33/35 pacientes com pangastrite (94,3%). A gastrite foi leve em 23/35 (65,7%) e moderada em 12/35 (34,3%). Gastrite atrófica histológica foi observada em 5/35 (14,3%) pacientes e metaplasia intestinal em 4/35 (11,4%). Todos os pacientes com metaplasia intestinal possuíam gastrite atrófica. Dos 35 pacientes em que se obteve sucesso de acesso endoscópico do estômago excluso, observou-se positividade para o Helicobacter pylori em 7/35 pacientes (20%) e no coto gástrico proximal em 12/35 pacientes (34,3%), através da histologia e coloração por Giemsa modificado. Todos os pacientes Helicobacter pylori positivos no estômago excluso, foram positivos no coto gástrico proximal. Não se observou significância estatística na correlação entre os achados endoscópicos e histológicos (p = 0,2). Das variáveis estudadas, observou-se que a intensidade da gastrite histológica (inflamação) do estômago excluso e do coto gástrico proximal associou-se à presença de Helicobacter pylori (p < 0,05), assim como todos os pacientes Helicobacter pylori positivos no estômago excluso também foram positivos no coto gástrico proximal (p = 0,0005). Não houve complicações durante e após o procedimento de endoscopia de duplo balão. Em conclusão, o método de endoscopia de duplo balão tem elevada capacidade de alcançar o estômago excluso dos pacientes submetidos à gastroplastia vertical com derivação gastrojejunal em Y de Roux; os achados endoscópicos e histológicos indicam alta prevalência de gastrite crônica, atrofia e metaplasia intestinal no estômago excluso desta população selecionada; o Helicobacter pylori está presente no estômago excluso após derivação gástrica em Y de Roux e todos aqueles Helicobacter pylori positivos no estômago excluso também foram positivos no coto gástrico proximal; e a intensidade da inflamação do estômago excluso e do coto gástrico proximal associou-se à presença de Helicobacter pylori. / The surgical treatment for morbid obesity is the only modality that in the long term obtains the supported loss of weight and maintenance. Vertical banded Roux-en-Y gastric bypass is the most used technique worldwide and in Brazil. Through this technique, the stomach is divided in two assimetrical pouchs, one vertical and tubular with about 5 cm of extension and another called excluded. The endoscopic follow-up during the postoperative period using standard gastroscope evaluates the proximal gastric pouch, but doesn\'t reach the excluded stomach. With the advent of the double balloon enteroscope, it became possible the access and endoscopic evaluation, allowing biopsies of the excluded stomach mucosa for histopathologic study. Forty patients who underwent vertical banded Roux-en-Y gastric bypass were enrolled in this study. The mean postoperative time was 77.3 months (36-133 months). The mean age was 44.6 years old (22-61 years) and 85% of the patients were female. The success rate of accessing the excluded stomach with the use of double balloon enteroscope was 87.5% (35 patients), and the mean time to reach the excluded stomach was 24.9 minutes (5-75 minutes). The concomitant radioscopic control was used in 11 patients (27.5%). Endoscopic findings of the excluded stomach in the 35 patients were: normal in 25.7% patients (9); enantematous gastritis were found in 10 patients (28.6%); flat or raised erosive gastritis in 5 patients (14.3%); hemorrhagic gastritis in 5 patients (14.3%) and atrophic gastritis in 6 patientes (17.1%). Two patients presented with suggestive areas of intestinal metaplasia in the antrum that had been confirmed by histopathologic study. The histologic findings showed 100% of gastritis in the excluded stomach; 33/35 patients with pangastritis (94.3%). Mild gastritis was present in 23/35 patients (65.7%) and moderate gastritis in 12/35 (34.3%). Atrophic gastritis were found in 5/35 patients (14.3%) and intestinal metaplasia in 4-35 (11.4%). All patients with intestinal metaplasia had atrophic gastritis. Of the 35 patients whom the excluded stomach were reached, Helicobacter pylori was positive in 7/35 patients (20%) and in 12/35 patients (34,3%) in the proximal pouch through the modified Giemsa staining. Statistical significance was not observed in the correlation between the endoscopic and histologic findings (p=0,2). The intensity of the histologic gastritis (inflammation) of the excluded stomach and the proximal pouch was associated to the presence of Helicobacter pylori (p < 0,05). All positive Helicobacter pylori patients in the excluded stomach were also positive in the proximal pouch (p = 0,0005). There were no complications during or after the procedure of double balloon endoscopy. In conclusion, the double balloon method has good success rate of access to the excluded stomach after vertical banded Roux-en-Y gastric bypass; the endoscopic and histologic findings indicate high prevalence of chronic gastritis, atrophy and intestinal metaplasia in the excluded stomach in this selected population; the Helicobacter pylori is present in the excluded stomach after Roux-en-Y gastric bypass; all patients positive for Helicobacter pylori in the excluded stomach were positive in the proximal pouch; and the intensity of inflammation of the excluded stomach and the proximal pouch associate with the presence of Helicobacter pylori.

Made available in DSpace on 2016-01-26T12:51:43Z (GMT). No. of bitstreams: 1 sidneypinheirojunior_tese.pdf: 1185692 bytes, checksum: 2cae9b38515819abe487b6260ac74acc (MD5) Previous issue date: 2012-03-27 / Background Outstanding, among the factors associated to cholelithiasis after bariatric surgery, are those related to metabolism and synthesis of lipoproteins, such as apolipoprotein E (ApoE) and protein from cholesterol ester transfer protein (CETP). Methods - 220 patients have been part of the study, 114 (G1) with cholelithiasis postoperatively and 106 (G2) without cholelithiasis in over 8 months period, including the analysis of apoE-Hha I and CETP-TaqIB polymorphisms per PCR / RFLP and biochemical profile [total cholesterol (TC), lipoprotein cholesterol fraction of low (LDL), high (HDLc) and very low density (VLDLc), triglycerides (TG) and glucose levels. It was accepted level of significance for P <0.05. Results - Preoperatively, it was observed that in G1 54% of the patients with the APOE*4 allele had serum altered levels of LDL. Postoperatively, there was a decrease (P <0.001) of LDL with TG in G2 (85.3 ± 32.1 mg / dL, P <0.0001) and glucose (G1 = 83.2 ± 10.7 mg / dL; G2 = 84.7 ± 11.5 mg / dL, P <0.0001 for both), TC and LDL and HDL cholesterol increased only in G2 (P <0.0001). The B1 allele was related to decreased (P <0.01) of TC, LDLc and TG postoperatively in both groups, in addition to lowering glucose levels and increase HDL cholesterol only in G2 (P <0.0001). The genotype APOE*_/4 in G2 was associated with decreased levels of TC, LDL, TG and glucose levels and increased levels of HDL cholesterol (P<0.01) postoperatively. Conclusions - This study does not confirm the association of apoE-Hha-I and CETP-TaqIB with gallstones in the late postoperative period after bariatric surgery. However, B1 allele seems to enhance the action of bariatric surgery in the control of dyslipidemia effectively reducing levels of TC, LDL and TG, with additional benefit to those without gallstones by decreasing blood glucose levels and also increase HDL cholesterol. The relationship of APOE*4 with increased LDLc preoperatively only in G1 suggests its association with cholelithiasis in the late postoperative bariatric surgery, which should be evaluated in prospective studies. / Introdução- Destacam-se entre os fatores associados à colelitíase após cirurgia bariátrica, aqueles relacionados a metabolismo e síntese de lipoproteínas plasmáticas, como apolipoproteína E (apo E) e proteína de transferência do éster de colesterol (CETP). Objetivos-Avaliar a associação das variantes genéticas apoE-Hha I e CETP-TaqIB na colelitíase e sua influência no perfil bioquímico,além de perfil antropométrico e co-morbidades em pacientes com obesidade mórbida após cirurgia bariátrica. Métodos- Foram estudados 220 pacientes: 114 (G1) com colelitíase no pós-operatório e 106 (G2) sem colelitíase, em período >8 meses, incluindo a análise dos polimorfismos apoE-HhaI e CETP-TaqIB por PCR/RFLP e perfil bioquímico [colesterol total (CT), fração de colesterol de lipoproteína de baixa (LDLc), alta (HDLc) e muito baixa densidade (VLDLc), triglicérides (TG) e glicemia], além do índice de massa corporal (IMC), cintura abdominal (CA), hipertensão e diabete melito. Admitiu-se nível de significância para P<0,05. Resultados- Houve semelhança entre os grupos para os genótipos de apoE-HhaI e CETP-TaqIB. O genótipo APOE*3/3 prevaleceu em ambos os grupos (G1: 65% e G2:73%; P=0,204), enquanto genótipos APOE*_/4 destacaram-se em G1 (23% versus 16%; P=0,269). Para CETP o alelo B1 prevaleceu em G1 (0,59) e G2 (0,62; P=0,558). O perfil bioquímico, com valores recomendados já no pré-operatório em ambos os grupos, exceto para TG (141,4±75,4; 159,3±90,9mg/dL, respectivamente, P=0,123) e glicemia (113,0±53,2; 105,8±34,3mg/dL, respectivamente; P=0,262), mostrou decréscimo (P<0,001) no pós-operatório para todas as variáveis, incluindo TG (respectivamente, 89,0±34,6mg/dL; 85,3±32,1mg/dL; P<0,0001 para ambos) e glicemia (respectivamente, 83,2±10,7mg/dL; 84,7±11,5mg/dL; P<0,0001 para ambos). Níveis de HDLc mostraram acréscimo no pós-operatório apenas em G2 (52,5±14,7 versus 43,0±11,9; P<0,0001). Em G1, 54% dos pacientes portadores do alelo APOE*4 tinham níveis séricos alterados de LDLc no pré-operatório. O genótipo APOE*3/3, em G1, associou-se com decréscimo nos níveis de CT, LDLc, TG e glicemia e aumento nos níveis de HDLc (P<0,01). O mesmo ocorreu para genótipos APOE*_/4, em G2. O alelo B1 relacionou-se com decréscimo (P<0,01) de CT, LDLc e TG no pós-operatório em ambos os grupos, além de redução de glicemia e aumento de HDLc apenas em G2 (P<0,0001).Ambos os grupos mostraram redução nos valores de IMC e CA, além de hipertensão e diabete melito. Conclusões: Variantes de apoE-HhaI e CETP-TaqIB não diferenciam os grupos com e sem colelitíase no pós-operatório tardio de cirurgia bariátrica. Presença de APOE*4 relacionada com aumento de LDLc no pré-operatório, sugere sua influência no desenvolvimento de colelitíase no pós- operatório tardio, a ser confirmado em estudos prospectivos. CETP-Taq IB, representado pelo alelo B1 parece potencializar a ação da cirurgia bariátrica no controle do perfil bioquímico, particularmente em G2 com aumento de HDLc e decréscimo da glicemia. Além disso, independente da presença de colelitiase, a cirurgia bariátrica controla também doenças crônicas como diabete melito e hipertensão arterial.